| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WALDBRONN, Germany—Key to determining the safety of a drug is knowing how it will behave with the human body or its ADME properties. In vitro, this determination generally involves LC/MSn techniques, but while the instruments have advanced greatly, the ability to rapidly interpret the resulting data has not.
 
Thus, researchers at Agilent Technologies devised a systematic approach to metabolite identification by LC/MSn that integrates automated software-aided data interpretation. They presented their work in the Journal of Mass Spectrometry (2006, 41, 248-255).
 
The researchers monitored the metabolism of the well characterized drug buspirone in extracts from rat cells using capillary LC coupled to ion trap and ESI-TOF MS and analyzed the data with ACD/MS Manager and ACD/ChemSketch software. Using these conditions, they were able to identify novel ion peaks that coeluted with major products and might have been missed through manual inspection. Thus, the combination of analytical and chemometric methods opens the possibility of identification of novel products that might have ADME implications.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue